LACTB and LC3 could serve as potential biomarkers of gastric cancer to neoadjuvant chemotherapy with oxaliplatin plus S‑1

Abstract

The present study investigated and evaluated the correlation between the expression of LACTB and LC3 and the clinical outcomes of patients with advanced gastric cancer treated with oxaliplatin plus S-1 neoadjuvant chemotherapy (NACT). A total of 51 patients with advanced gastric cancer underwent NACT treatment between June 2015 and June 2017. Pathomorphological changes in gastric cancer were analyzed by H&E staining. The expression level and subcellular localization of LACTB and LC3 in paraffin-embedded biopsies were detected by immunohistochemistry and immunofluorescence. The mRNA and protein expression of LACTB were investigated by reverse transcription quantitative polymerase chain reaction and Western blotting, respectively. Statistical analysis was performed to determine the association between the expression of LACTB and LC3 and clinical chemotherapy efficacy of NACT for gastric cancer. Among the 51 patients, 3 (5.88%), 27 (52.94%), 13 (25.49%) and 8 (15.69%) displayed complete remission, partial remission, stable disease and progressive disease, respectively. The rate of decreased LACTB expression was 68.6%, while the rate of increased LC3 expression was 60.8%. Furthermore, there was a significant negative correlation between the expression of LACTB and that of LC3 following NACT (P<0.001). High expression of LC3 (P<0.01) and low expression of LACTB (P<0.01) were associated with a poor response of patients with advanced gastric cancer to NACT. In conclusion, the expression of LACTB and LC3 may serve as a promising novel biomarker for determining the prognosis of patients with advanced gastric cancer receiving NACT, while its potential clinical significance requires further elucidation.

Structural basis for the catalytic activity of filamentous human serine beta-lactamase-like protein LACTB

“…Based on previous research, LACTB is considered as a tumor suppressor in breast cancer, possibly through the regulation of lipid metabolism (Keckesova et al, 2017). In addition, LACTB dysregulation in melanoma, gastric cancer, glioma cancer, and colorectal cancer patients can serve as a marker for tumor development and prognosis (Jiang et al, 2020;Li et al, 2019;Ma et al, 2021;Wang et al, 2020;Xu et al, 2020;Yang et al, 2021aYang et al, , 2021bZeng et al, 2018). Moreover, LACTB overexpression has been shown to contribute to several cancers, including nasopharyngeal carcinoma and pancreatic adenocarcinoma (Peng et al, 2021;Xie et al, 2021).…”

Unveiling the Function of the Mitochondrial Filament-Forming Protein LACTB in Lipid Metabolism and Cancer

“…Likewise, a low expression level of LACTB correlated with a poor prognosis in hepatocellular carcinoma and overexpression of LACTB in hepatocellular carcinoma cells resulted in the inhibition of proliferation, migration and invasion [30]. Similar results supporting a tumour suppressive effect of increased LACTB expression have been obtained for melanoma [31,32], gastric cancer [33,34], and lung cancer [35].…”

The interplay between autophagy and cGAS-STING signaling and its implications for cancer

“…In comparison, high autophagy rates correlate with poor survival, lymph node metastasis and hepatic metastasis in gastric cancer ( 316 ). Low LACTB expression and high LC3 levels are associated with poor patient responses to neoadjuvant chemotherapy ( 317 ). However, in multiple myeloma, patients with strong immunoreactivity to Beclin-1 or LC3 show significantly improved overall survival compared to those with medium or low levels of Beclin-1 or LC3 ( 318 ).…”